Literature DB >> 31161827

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

Matteo Dragani1, Giovanna Rege-Cambrin1, Dario Ferrero2, Elisabetta Abruzzese3, Patrizia Pregno4, Chiara Elena5, Michele Cedrone6, Marco Santoro7, Giacomo Andreani1, Giuseppe Saglio1, Carmen Fava1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31161827     DOI： 10.1080/10428194.2019.1622103

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR.

Authors:  Aleksandar Jovanovski; Jessica Petiti; Emilia Giugliano; Enrico Marco Gottardi; Giuseppe Saglio; Daniela Cilloni; Carmen Fava
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639

Review 2.  Prospects for achieving treatment-free remission in chronic myeloid leukaemia.

Authors:  Giuseppe Saglio; Robert P Gale
Journal:  Br J Haematol       Date:  2020-02-14       Impact factor: 6.998

Review 3.  Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice.

Authors:  Camille C B Kockerols; Peter J M Valk; Mark-David Levin; Niels Pallisgaard; Jan J Cornelissen; Peter E Westerweel
Journal:  Hemasphere       Date:  2020-11-24

4.  Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia.

Authors:  Dawne N Shelton; Prasanthi Bhagavatula; Nathan Sepulveda; Lan Beppu; Shital Gandhi; Dahui Qin; Scott Hauenstein; Jerald Radich
Journal:  PLoS One       Date:  2022-03-17       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.